Antibodies targeting talaromyces marneffei mp1p protein and methods of use thereof
US-2024199726-A1 · Jun 20, 2024 · US
Therapeutic antibodies against ROR-1 protein and methods for use of same
US9217040B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9217040-B2 |
| Application number | US-201213997934-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 13, 2012 |
| Priority date | Jan 14, 2011 |
| Publication date | Dec 22, 2015 |
| Grant date | Dec 22, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Therapeutic antibodies having binding specificity for ROR-1 expressed on cancer cells (particularly leukemic and lymphomic cells) and pharmaceutical compositions containing one or more such antibodies for use in treating cancer. Methods for diagnosing such cancers through in vitro detection of binding to ROR-1 protein expressed on putative cancer cells are also provided.
First claim
Opening claim text (preview).
What is claimed is: 1. An isolated antibody that specifically binds receptor tyrosine kinase like orphan receptor one (ROR1) protein and comprises a heavy chain variable region comprising SEQ ID NO:14 and a light chain region comprising SEQ ID NO:16. 2. The antibody according to claim 1 , wherein it further specifically binds either the 3′ or middle Ig-like region of the extracellular domain of human or murine ROR-1 protein. 3. The antibody…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Human Necessities · mapped topic
- G01N33/6854Primary
Physics · mapped topic
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9217040B2 cover?
- Therapeutic antibodies having binding specificity for ROR-1 expressed on cancer cells (particularly leukemic and lymphomic cells) and pharmaceutical compositions containing one or more such antibodies for use in treating cancer. Methods for diagnosing such cancers through in vitro detection of binding to ROR-1 protein expressed on putative cancer cells are also provided.
- Who is the assignee on this patent?
- Kipps Thomas J, Widhopf Ii George F, Cui Bing, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification G01N33/6854. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Dec 22 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).